SEC EDGARSep 8$TENX

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.6M of TENX (indirect holdings)

ADAR1 Capital Management, LLC purchased 900,000 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at $1.78 ($1.60M total) on 2026-09-03. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting

SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel

Published Sep 8, 2026, 9:16 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 8, 2026, 9:39 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TENX

Neutral

medium confidence

Mentioned

$TENX

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TENXNeutralLow

Why it matters

The disclosed purchase adds to ADAR1's stake, indicating continued confidence but limited market impact.

Market read

Small insider buy; modest relevance for traders monitoring TENX.

What to watch

The purchase is indirect and may reflect broader fund rebalancing rather than company-specific optimism.

Relevance 7/10Novelty 5/10Timing: post-filing on 2026-09-08

Background

Form 4 filings disclose insider transactions; ADAR1 Capital Management is a 10% owner of TENX.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TENXNeutralMedium confidence

Context

SEC Form 4 shows ADAR1 Capital Management bought 900,000 TENX shares at $1.7824, totaling $1.6M, raising its stake to 6.5M shares.

Expected impact

Potential slight upside pressure, unlikely to move price materially.

Evidence & confidence

A $1.6M buy by a 10% owner is a positive signal, but the amount is small for a listed biotech.

Market effects

Sector

Minor signal for biotech sector; no broader impact.

Regional

U.S. market only; negligible regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio adjustment, not a strong endorsement.

Key entities

Investor
ADAR1 Capital Management, LLC
10% owner of TENX filing a Form 4 purchase.
Company
TENAX THERAPEUTICS, INC.
Biotech firm listed under ticker TENX.

Read at source ← All news

$TENXMed

Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

TENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the

SEC EDGAR 8-KNov 5

$TENXLow

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.5M of TENX (indirect holdings)

ADAR1 Capital Management, LLC purchased 922,849 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.59 ($1.51–$1.66, $1.46M total) across 3 trades over 2026-10-19 to 2026-10-21. Filed jointly with Schneeberger Daniel (10% owner).

SEC EDGAROct 21

$TENXMedAI 8/10

Tenax Therapeutics pauses LEVEL-2 enrollment to implement enrichment after Phase 3 LEVEL learnings

Tenax Therapeutics (TENX) paused LEVEL-2 enrollment to update inclusion criteria based on Phase 3 LEVEL trial results. The company aims to target sicker PH-HFpEF patients after seeing benefits in this subgroup. Tenax plans to seek FDA feedback and updated its investor presentation. The pause is not related to safety concerns.

tradingview.comOct 8

$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.comSep 4

$TENXLow

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.4M of TENX (indirect holdings)

ADAR1 Capital Management, LLC purchased 770,333 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.79 ($1.79–$1.80, $1.38M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Schneeberger Daniel (10% owner).

SEC EDGARSep 2

$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.comAug 31